Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Malinin, Z. Li, R. Chapman, F. Leifer, D. Omiatek, J. Ong, D. Salvail, C. Laurent, W. Perkins (Monmouth Junction, United States Of America; Sherbrooke, Canada). Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations. Eur Respir J 2014; 44: Suppl. 58, 2367

Member's Comments

No comment yet.

Related content which might interest you: Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Epoprostenol dosing by concomitant therapies in the PROSPECT registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Population pharmacokinetics (PK) of riociguat in patients (pts) with renal and hepatic impairment Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Immune signatures in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Endothelial-to-mesenchymal transition in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Chronic thromboembolic vasculopathy with exercise induced PH but normal resting haemodynamics Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Long-term screening for pulmonary hypertension after pulmonary embolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Pulmonary arterial hypertension – A single-centre experience Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cells Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 An overview of thrombolytic treatment for pulmonary embolism: A single center experience Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Prognosis factors of recurrent pulmonary thromboembolism Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Long-term data from the Swiss pulmonary hypertension registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014